But the point is that the things President Trump has focused most on, intellectual property rights, is actually something TPP is pretty aggressive on. The point really isn’t the rights or wrongs of TPP. The point is that Trump had zero idea what TPP even was when he decided to peremptorily pull out of the agreement. It may have been bad for the US or good. But his decision was based on ignorance and impulse. Because there was nothing behind it in the first place, an about-face is completely possible.
For the record, I’m with Sasse: Trump “likes to blue-sky a lot.” That is to say, he was just spouting off and it probably means nothing. But it’s just one more example of the toll of a militantly ignorant President.
Goldman Sachs, everyone’s favorite Great Vampire Squid, notes that there isn’t much money in medical cures, only in endless courses of medical treatments:
"Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution."
"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."
Richter cited Gilead Sciences' treatments for hepatitis C, which achieved cure rates of more than 90 percent. The company's U.S. sales for these hepatitis C treatments peaked at $12.5 billion in 2015, but have been falling ever since. Goldman estimates the U.S. sales for these treatments will be less than $4 billion this year, according to a table in the report.